Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 4, 2008, Pages 664-675

  Svensson, Camilla I ^a   Medicherla, Satyanarayana ^c   Malkmus, Shelle ^a   Jiang, Yebin ^b   Ma, Jing Y ^c   Kerr, Irena ^c   Brainin Mattos, Josue ^a   Powell, Harry C ^a   Luo, Z David ^a   Chakravarty, Sarvajit ^c   Dugar, Sundeep ^c   Higgins, Linda S ^c   Protter, Andrew A ^c   Yaksh, Tony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c SCIOS INC   (United States)

Author keywords

Allodynia; Bone cancer; Dorsal root ganglion; Osteosarcoma; p38 MAPK; Pain; SCIO 469; Spinal cord

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; SCIO 469;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; BONE MARROW; BONE PAIN; CANCER PAIN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; SPINAL CORD; SPINAL GANGLION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BONE NEOPLASMS; CELL LINE, TUMOR; EATING; ENZYME ACTIVATION; ENZYME INHIBITORS; GANGLIA, SPINAL; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PAIN; PAIN MEASUREMENT; SENSORY THRESHOLDS; TOMOGRAPHY, X-RAY COMPUTED; VOCALIZATION, ANIMAL;

ANIMALIA; MUS;

EID: 48749095670     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.05.016     Document Type: Article

References (57)

1. Adams J.L., Badger A.M., Kumar S., and Lee J.C. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem 38 (2001) 1-60
2. Borsch-Haubold A.G., Ghomashchi F., Pasquet S., Goedert M., Cohen P., Gelb M.H., et al. Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stress-activated protein kinase pathways. Eur J Biochem 265 (1999) 195-203
3. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
4. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 (2001) 165-176
5. Ghilardi J.R., Rohrich H., Lindsay T.H., Sevcik M.A., Schwei M.J., Kubota K., et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25 (2005) 3126-3131
6. Grills B.L., and Schuijers J.A. Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone. Acta Orthop Scand 69 (1998) 415-419
7. Guan Z., Baier L.D., and Morrison A.R. p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1beta. J Biol Chem 272 (1997) 8083-8089
8. Halvorson K.G., Kubota K., Sevcik M.A., Lindsay T.H., Sotillo J.E., Ghilardi J.R., et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 65 (2005) 9426-9435
9. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98 (2000) 585-598
10. Hwang D., Jang B.C., Yu G., and Boudreau M. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages. Biochem Pharmacol 54 (1997) 87-96
11. Jiang Y., Zhao J., White D.L., and Genant H.K. Micro CT and micro MR imaging of 3D architecture of animal skeleton. J Musculoskel Neuron Interact 1 (2000) 45-51
12. Jiang Y., Zhao J., and Genant H.K. Macro and micro imaging of bone architecture. In: Bilezikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of Bone Biology. 2nd ed. (2002), Academic Press, San Diego, CA 1599-1623
13. Ji R.R., Samad T.A., Jin S.X., Schmoll R., and Woolf C.J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36 (2002) 57-68
14. Jin S.X., Zhuang Z.Y., Woolf C.J., and Ji R.R. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23 (2003) 4017-4022
15. Jin X., and Gereau R.W.t. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci 26 (2006) 246-255
16. Karsdal M.A., Hjorth P., Henriksen K., Kirkegaard T., Nielsen K.L., Lou H., et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278 (2003) 44975-44987
17. Kramer R.M., Roberts E.F., Um S.L., Borsch-Haubold A.G., Watson S.P., Fisher M.J., et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271 (1996) 27723-27729
18. Kumar S., Votta B.J., Rieman D.J., Badger A.M., Gowen M., and Lee J.C. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol 187 (2001) 294-303
19. Lee S.E., Woo K.M., Kim S.Y., Kim H.M., Kwack K., Lee Z.H., et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30 (2002) 71-77
20. Li X., Udagawa N., Itoh K., Suda K., Murase Y., Nishihara T., et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143 (2002) 3105-3113
21. Lucas K.K., Svensson C.I., Hua X.Y., Yaksh T.L., and Dennis E.A. Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. Br J Pharmacol 144 (2005) 940-952
22. Luger N.M., Mach D.B., Sevcik M.A., and Mantyh P.W. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage 29 (2005) S32-46
23. Mach D.B., Rogers S.D., Sabino M.C., Luger N.M., Schwei M.J., Pomonis J.D., et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113 (2002) 155-166
24. Matsumoto M., Sudo T., Maruyama M., Osada H., and Tsujimoto M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 486 (2000) 23-28
25. Matsumoto M., Sudo T., Saito T., Osada H., and Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275 (2000) 31155-31161
26. Medicherla S., Ma J.Y., Mangadu R., Jiang Y., Zhao J.J., Almirez R., et al. A selective p38 mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 318 (2006) 132-141
27. Nath P., Leung S.Y., Williams A., Noble A., Chakravarty S.D., Luedtke G.R., et al. Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. Eur J Pharmacol. 544 1-3 (2006) 160-167
28. Niiyama Y., Kawamata T., Yamamoto J., Omote K., and Namiki A. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience (2007)
29. Nishikawa M., Myoui A., Tomita T., Takahi K., Nampei A., and Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 48 (2003) 2670-2681
30. Obata K., Yamanaka H., Kobayashi K., Dai Y., Mizushima T., Katsura H., et al. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci 24 (2004) 10211-10222
31. Ono K., and Han J. The p38 signal transduction pathway: activation and function. Cell Signal 12 (2000) 1-13
32. Pantouli E., Boehm M.M., and Koka S. Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. Biochem Biophys Res Commun 329 (2005) 224-229
33. Parfitt A.M., Mathews C.H., Villanueva A.R., Kleerekoper M., Frame B., and Rao D.S. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 72 (1983) 1396-1409
34. Portenoy R.K., Payne D., and Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81 (1999) 129-134
35. Rennefahrt U., Janakiraman M., Ollinger R., and Troppmair J. Stress kinase signaling in cancer: fact or fiction?. Cancer Lett 217 (2005) 1-9
36. Sabino M.A., Ghilardi J.R., Jongen J.L., Keyser C.P., Luger N.M., Mach D.B., et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62 (2002) 7343-7349
37. Safieh-Garabedian B., Poole S., Allchorne A., Winter J., and Woolf C.J. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115 (1995) 1265-1275
38. Schafers M., Svensson C.I., Sommer C., and Sorkin L.S. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 23 (2003) 2517-2521
39. Scholz J., and Woolf C.J. Can we conquer pain?. Nat Neurosci 5 Suppl (2002) 1062-1067
40. Schultz R.M. Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog Drug Res 60 (2003) 59-92
41. Schwei M.J., Honore P., Rogers S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19 (1999) 10886-10897
42. Selvamurugan N., Fung Z., and Partridge N.C. Transcriptional activation of collagenase-3 by transforming growth factor-beta1 is via MAPK and Smad pathways in human breast cancer cells. FEBS Lett 532 (2002) 31-35
43. Sorkin L.S., Xiao W.H., Wagner R., and Myers R.R. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81 (1997) 255-262
44. Suarez-Cuervo C., Merrell M.A., Watson L., Harris K.W., Rosenthal E.L., Vaananen H.K., et al. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 21 (2004) 525-533
45. Svensson C.I., Hua X.Y., Protter A.A., Powell H.C., and Yaksh T.L. Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. Neuroreport 14 (2003) 1153-1157
46. Svensson C.I., Marsala M., Westerlund A., Calcutt N.A., Campana W.M., Freshwater J.D., et al. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 86 (2003) 1534-1544
47. Sweitzer S.M., Peters M.C., Ma J.Y., Kerr I., Mangadu R., Chakravarty S., et al. Peripheral and central p38 MAPK mediates capsaicin-induced hyperalgesia. Pain 3 (2004) 278-285
48. Takeshita S., Namba N., Zhao J., Jiang Y., Genant H.K., Silva M.J., et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 8 (2002) 943-949
49. Tsuda M., Mizokoshi A., Shigemoto-Mogami Y., Koizumi S., and Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 45 (2004) 89-95
50. Vit J.P., Ohara P.T., Tien D.A., Fike J.R., Eikmeier L., Beitz A., et al. The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception. Pain 120 (2006) 188-201
51. Vanderkerken K., Medicherla S., Coulton L., Menu E., Protter A.A., Higgins L.S., et al. Inhibition of p38 MAPK prevents the development of myeloma bone disease, reduces tumor burden and increases survival in murine models of myeloma. Cancer Res 67 (2007) 4572-4577
52. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79 (1999) 143-180
53. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 288 (2000) 1765-1769
54. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 34 (1998) 240-245
55. Zhang R.X., Liu B., Wang L., Ren K., Qiao J.T., Berman B.M., et al. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 118 (2005) 125-136
56. Zwerina J., Hayer S., Redlich K., Bobacz K., Kollias G., Smolen J.S., et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 54 (2006) 463-472
57. Zwerina J., Hayer S., Redlich K., Bobacz K., Kollias G., Smolen J.S., et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 54 (2006) 463-472